Email this article Molecular mechanisms of hemostasis impairment in oncology
- Authors: Koltsova E.M.1,2, Svidelskaya G.S.1,2, Shifrin Y.A.1, Ataullakhanov F.I.1,2
-
Affiliations:
- Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
- Center for Theoretical Problems of Physicochemical Pharmacology, Russian Academy of Sciences
- Issue: Vol 20, No 4 (2021)
- Pages: 191-198
- Section: LITERATURE REVIEW
- Submitted: 22.12.2021
- Accepted: 22.12.2021
- Published: 22.12.2021
- URL: https://hemoncim.com/jour/article/view/574
- DOI: https://doi.org/10.24287/1726-1708-2021-20-4-191-198
- ID: 574
Cite item
Full Text
Abstract
Malignant neoplasms are characterized by the presence of the hemostasis system pathology, predisposing cancer patients to thrombohemorrhagic complications. The pathogenesis of cancer-associated coagulopathy is complex and involves a variety of mechanisms. Tumor cells have the ability to activate the host’s hemostasis system, and this phenomenon is controlled by the same oncogenes that are responsible for neoplastic transformation. In addition to predisposing factors to impaired hemostasis from the side of the disease, the anticancer drugs themselves carry risks of developing coagulation disorders. The pathophysiological basis of this kind of disorders caused by chemotherapy is associated with damage to the endothelium, imbalance of coagulation and anticoagulant proteins, platelet dysfunction and their deficiency. In this article, the authors set themselves the goal of generalizing and updating the current knowledge of the molecular mechanisms that cause thrombohemorrhagic risk in cancer.
About the authors
E. M. Koltsova
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation;Center for Theoretical Problems of Physicochemical Pharmacology, Russian Academy of Sciences
Author for correspondence.
Email: ekaterina_koltsova@bk.ru
ORCID iD: 0000-0003-0167-6726
leading researcher of the Laboratory of Translational Medicine, 1 Samory Mashela St., Moscow 117997;
Deputy Director of Science–Scientific Secretary, Moscow
Russian FederationG. S. Svidelskaya
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation;Center for Theoretical Problems of Physicochemical Pharmacology, Russian Academy of Sciences
ORCID iD: 0000-0001-9744-9629
1 Samory Mashela St., Moscow 117997
Russian FederationYu. A. Shifrin
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
ORCID iD: 0000-0002-0053-0146
1 Samory Mashela St., Moscow 117997
Russian FederationF. I. Ataullakhanov
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation;Center for Theoretical Problems of Physicochemical Pharmacology, Russian Academy of Sciences
ORCID iD: 0000-0003-3403-181X
1 Samory Mashela St., Moscow 117997
Russian FederationReferences
Supplementary files
